1. Experiences on „tech transfer“ at
the Institute of Organic
Chemistry and Biochemistry CAS
Martin Fusek

2. IOCB
●Located in Prague, Flemingovo nám.
●Part of Czech Academy of Sciences
●Currently 530 employes, app 400 scientists and
students
●Mission – basic research in the areas of organic
chemistry, biochemistry, chemistry of natural
compounds and theoretical chemistry with strong
emphasis on application of the results for better
human life.

3. Research at IOCB
● Main areas:
●Medicinal chemistry = 40 % of the institute
●Organic synthesis = novel reactions and compounds for
e.g. „nano-elektronics“, novel agricultural applications
etc.
●Biochemistry – fundamental processes connected to
various pathologies (HIV, other viral diseases, microbial
infections)
●Chemistry of natural compounds – e.g. Insect signalling
and its application in defense of cultural plants
●Theoretical chemistry – experiments „in silico“

4. Tech transfer history of IOCB

5. Collaboration with company Gilead
Sciences
●Gilead Sci.– today company with sales around
15 bil USD, most of it based on discoveries of
prof. A. Holý.
●Since early eighties
●Friendship
●License agreements
●Now – income for the IOCB - „royality stream“ +
GSRC – scientific collaboration

6. IOCB TTO s.r.o.
●Incorporated – August 2009
●Functional – January 2010
●People
●Director
●Patent attorney
●Administrative
●New person entering in November
●Status
●100 % owned by IOCB

7. Results
●IP protection system
●25 Patent applications
●13 Patents awarded
●3 licenses signed
●Grants (TACR)
●Management „CDOD“

8. experiences
●Be there
●Informal relationship with researchers
●Understanding their problems
●Transparent / Integral
SCIENCE
●

9. Current projects
Projects (medicinal chemistry) :
●
●Antivirotics
●Anti-inflamatory compounds
●Neuroprotectives
●Antimikrobial compounds
●Anti-cancer compounds
GAP
●

10. THE GAP
p t tion
nce iza al
h pti
m ic I II III IV
arc f co do clin Clin Clin Clin Clin
get ese Lea
d fo Pre
Tar icr Pro
o Lea
Bas
Academia – mostly finishes Pharma – mostly wants clin I
at the proof of concept phase results

12. Ways to deal with GAP
●CDOD
●Spin-off ? „+“ and „-“
●Internal spin-off

13. Thank you for your attention!
Kontakty :
Prof. Ing. Martin Fusek, CSc
IOCB TTO s.r.o.
Flemingovo nam. 2, 16610 Prague 6, CR
Email : fusekmartin@seznam.cz
www.iocb-tto.cz